+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Menorrhagia - Pipeline Insight, 2021

  • ID: 5237631
  • Drug Pipelines
  • January 2021
  • Region: Global
  • 60 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

This “Menorrhagia - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Menorrhagia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Menorrhagia Understanding

Menorrhagia: Overview

Menorrhagia is heavy or prolonged menstrual bleeding that lasts for more than 7 days. It limits normal activities, affects quality of life, and causes anaemia in two-thirds of women with objective menorrhagia. It can be caused due to:
1. Problems related to uterine
  • Growths or tumors of the uterus that are not cancer; these can be called uterine fibroids or polyps.
  • Cancer of the uterus or cervix.
  • Certain types of birth control - for example, an intrauterine device (IUD).
  • Problems such as a miscarriage or ectopic pregnancy, can also cause abnormal bleeding.
2. Hormone-related problems
3. Other illnesses
  • Bleeding-related disorders, such as von Willebrand disease (VWD) or platelet function disorder.
  • Nonbleeding-related disorders such as liver, kidney, or thyroid disease; pelvic inflammatory disease; and cancer.
Symptoms

Signs and symptoms of menorrhagia may include:
  • Soaking through one or more sanitary pads or tampons every hour for several consecutive hours
  • Needing to use double sanitary protection to control your menstrual flow
  • Needing to wake up to change sanitary protection during the night
  • Bleeding for longer than a week
  • Passing blood clots larger than a quarter
  • Restricting daily activities due to heavy menstrual flow
  • Symptoms of anemia, such as tiredness, fatigue or shortness of breath
Diagnosis

Usually, menstrual bleeding lasts about 4 to 5 days and the amount of blood lost is small (2 to 3 tablespoons). However, women who have menorrhagia usually bleed for more than 7 days and lose twice as much blood. The doctor will ask about the medical history and bleeding cycles. The diagnosis involves one or more tests or procedures such as: blood test, pap test, endometrial biopsy, and ultrasound. Based on the results of primary tests, further tests such as Sonohysterography and Hysteroscopy can be recommended.

Treatment

The type of treatment is based on the cause of bleeding and its severity. Other factors such as age, medical history and overall health will also be considered. Treatment for hormone problems may include: Prostaglandin inhibitors are nonsteroidal anti-inflammatory medicines (NSAIDs), including aspirin or ibuprofen. They help reduce cramping and the amount you bleed. Ablation, Hysterectomy Birth control pills helps to stop ovulation and result in lighter periods. Treatment for problems with the uterine lining (endometrium), hysterectomy, and iron supplements

Menorrhagia Emerging Drugs Chapters

This segment of the Menorrhagia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Menorrhagia Emerging Drugs

Elagolix: Abbvie

Elagolix is an orally-administered, nonpeptide, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist that inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. Administration results in dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased blood concentrations of the ovarian sex hormones estradiol and progesterone. It is registered for menorrhagia.

Menorrhagia: Therapeutic Assessment

This segment of the report provides insights about the different Menorrhagia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Menorrhagia

There are approx. 5+ key companies which are developing the therapies for Menorrhagia. The companies which have their Menorrhagia drug candidates in the mid to advanced stage, i. e. phase III and Phase II include, Abbvie and others.

Phases

This report covers around 10+ products under different phases of clinical development like
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Menorrhagia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Menorrhagia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Menorrhagia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Menorrhagia drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Menorrhagia R&D. The therapies under development are focused on novel approaches to treat/improve Menorrhagia.
Menorrhagia Report Insights
  • Menorrhagia Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Menorrhagia Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Menorrhagia drugs?
  • How many Menorrhagia drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Menorrhagia?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Menorrhagia therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Menorrhagia and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Abbvie
Key Products
  • Elagolix

This report will be delivered within 1-3 business days
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

Introduction

Executive Summary

Menorrhagia: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Menorrhagia - Analytical Perspective

In-depth Commercial Assessment
  • Menorrhagia companies’ collaborations, Licensing, Acquisition - Deal Value Trends
Menorrhagia Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
  • Product Description
  • Research and Development
  • Product Development Activities
Pre-clinical and Discovery Stage Products
  • Comparative Analysis
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Menorrhagia Key Companies

Menorrhagia Key Products

Menorrhagia- Unmet Needs

Menorrhagia- Market Drivers and Barriers

Menorrhagia- Future Perspectives and Conclusion

Menorrhagia Analyst Views

Menorrhagia Key Companies

Appendix

List of Tables
Table 1 Total Products for Menorrhagia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Menorrhagia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
3 of 3
  • Abbvie
Note: Product cover images may vary from those shown
Adroll
adroll